Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 6/2000

Open Access 01-12-2000 | Research article

Estrogen receptor of primary breast cancers: evidence for intracellular proteolysis

Authors: Younes Maaroufi, Marc Lacroix, Laurence Lespagnard, Fabrice Journé, Denis Larsimont, Guy Leclercq

Published in: Breast Cancer Research | Issue 6/2000

Login to get access

Statement of findings

Iodinated oestradiol-labeled oestrogen receptor (ER) isoforms devoid of amino-terminal ABC domains represent about two-thirds of the whole receptor population detected in cytosol samples from human breast cancers. This high frequency could not be ascribed to the expression of truncated mRNAs, or to the proteolysis of the native ER peptide at the time of homogenization or assay, suggesting an intracellular proteolysis. Free amino-terminal and ligand-binding domains maintained together within oligomeric structure(s); increase of ionic strength separated them. The amino-terminal region was consistently detected in the cell nucleus by specific immunohistochemistry leading to the concept of a potential intranuclear association between ER cleavage products and/or other regulatory proteins.
Literature
1.
Heuson JC, Leclercq G, Longeval E, Deboel MC, Mattheiem WH, Heimann R (Edited by McGuire WL, Carbone PP, Volmer EP New York: Raven Press): Estrogen receptors: pronostic significance in breast cancer. In: Estrogen Receptors in Human Breast Cancer. 1975, 57-72.
2.
McGuire WL: Hormone receptors: their role in predicting prognosis and response to endocrine therapy. Semin Oncol. 1978, 5: 428-433.PubMed
3.
DeSombre ER, King WJ, Green GL, Jensen EV (Edited by Jordan VC Wisconsin: University of Wisconsin Press): Estrogen receptor studies. Laboratory investigations and clinical applications. In: Estrogen/Antiestrogen Action and Breast Cancer Therapy. 1986, 303-323.
4.
Leclercq G, Bojar H, Goussard J, Nicholson RI, Pichon MF, Piffanelli A, Pousette A, Thorpe S, Lonsdorfer M: Abbott monoclonal enzyme immunoassay measurement of estrogen receptors in human breast cancer: a european multicenter study. Cancer Res. 1986, 46 (Suppl): S4233-S4236.
5.
al Saati T, Clamens S, Cohen-Knafo E, Faye JC, Prats H, Coindre JM, Wafflart J, Caveriviere P, Bayard F, Delsol G: Production of monoclonal antibodies to human estrogen-receptor protein (ER) using recombinant ER (RER). Int J Cancer. 1993, 55: 651-654.CrossRefPubMed
6.
Kell DI, Kamel OW, Rouse RV: Immunohistochemical analysis of breast carcinoma estrogen and progesterone receptors in paraffin-embedded tissues: correlation of clones ER1D5 and 1A6 with a cytosol-based hormone receptor assay. Appl Immunohistochem. 1993, 1: 275-281.
7.
Wong SY, Purdie A, Sewell HF, Wilkinson L, Angus B, Westley B, Horne CH: Immunohistochemical assessment of ER-P31, a mouse anti-oestrogen receptor protein monoclonal antibody in human breast cancers: comparison with ER-ICA (Abbott) and radioligand assays. Tumor Biol. 1991, 12: 16-23.CrossRef
8.
Clark GM, McGuire WL: Steroid receptors and other pronostic factors in primary breast cancer. Semin Oncol. 1988, 15: 20-25.PubMed
9.
10.
Sluyser M, Wittliff JL: Influence of estrogen receptor variants in mammary carcinomas on the pronostic reliability of the receptor assay. Mol Cell Endocrinol. 1992, 85: 83-88.CrossRefPubMed
11.
Maaroufi Y, Trivedi S, Leclercq G: Major molecular weight heterogeneity of estrogen receptor from breast cancer is not related to neoplasia. Cancer Biochem Biophys. 1995, 15: 67-78.PubMed
12.
Maaroufi Y, Leclercq G: Importance of A/B and C domains of the estrogen receptor for its adsorption to hydroxylapatite. J Ster Bioch Mol Biol. 1994, 48: 155-163.CrossRef
13.
Murayama A, Fukai F, Murachi T: Action of calpain on the basic estrogen receptor molecule of porcine uterus. J Biochem. 1984, 95: 1697-1704.PubMed
14.
Thole HH, Maschler I, Jungblut PW: Surface mapping of the ligand-filled C-terminal half of the porcine estradiol receptor by restricted proteolysis. Eur J Biochem. 1995, 231: 510-516.CrossRefPubMed
15.
Seielstad DA, Carlson KE, Kushner PJ, Greene GL, Katzenellenbogen JA: Analysis of the structural core of the human estrogen receptor ligand binding domain by selective proteolysis/mass spectrometry analysis. Biochemistry. 1995, 34: 12605-12615.CrossRefPubMed
16.
Horigome TF, Ogata TS, Golding F, Korach KS: Estradiol-stimulated proteolytic cleavage of the estrogen receptor in mouse uterus. Endocrinology. 1988, 123: 2540-2548.CrossRefPubMed
17.
Wittliff JL, Savlov ED (Edited by McGuire WL, Carbone PP, Volmer EP New York: Raven Press): Estrogen binding capacity of cytoplasmic forms of estrogen receptors in human breast cancer. In: Estrogen Receptors in Human Breast Cancer. 1975, 73-86.
18.
Freedman B, Hawkins RA: Sedimentation profiles of the estrogen receptor from breast tumors of man and rat using vertical-tube rotor centrifugation. J Endocrinol. 1980, 86: 431-442.CrossRefPubMed
19.
Piccart MJ, Muquardt C, Bosman C, Pirotte P, Veenstra S, Grillo F, Leclercq G: Comparison between tritiated estradiol and tamoxifen aziridine for measuring estrogen receptors in human breast cancer cytosols. J Natl Cancer Inst. 1991, 83: 1553-1559.CrossRefPubMed
20.
Pahl HL, Bäuerle PA: Control of gene expression by proteolysis. Curr Opin Cell Biol. 1996, 8: 340-347.CrossRefPubMed
21.
22.
Plombella VJ, Rando OJ, Goldberg AL, Maniatis T: The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell. 1994, 78: 773-785.CrossRef
23.
24.
El Khissiin A, Leclercq G: Implication of proteasome in estrogen receptor degradation. FEBS Lett. 1999, 448: 160-166.CrossRefPubMed
25.
Nawaz Z, Lonard DM, Dennis AP, Smith CL, O'Malley BW: Proteasome-dependent degradation of the human estrogen receptor. Proc Natl Acad Sci USA. 1999, 96: 1858-1862.CrossRefPubMedPubMedCentral
26.
Alarid ET, Bakopoulos N, Solodin N: Proteasome-mediated proteolysis of estrogen receptor: a novel component in autologous down-regulation. Mol Endocrinol. 1999, 13: 1522-1534.CrossRefPubMed
27.
Wooge CH, Nilsson GM, Heierson A, McDonnell DP, Katzenellenbogen BS: Structural requirements for high affinity ligand binding by estrogen receptors: a comparative analysis of truncated and full length estrogen receptors expressed in bacteria, yeast, and mammalian cells. Mol Endocrinol. 1992, 6: 861-869.PubMed
28.
Leclercq G, Legros N, Piccart MJ: Accumulation of a non-binding form of estrogen receptor in MCF-7 cells under hydroxytamoxifen treatment. J Steroid Biochem Mol Biol. 1992, 41: 545-552.CrossRefPubMed
29.
EORTC: Breast Cancer Cooperative Group. Revision of the standards for the assessment of hormone receptors in human breast cancer. Eur J Cancer. 1980, 16: 1513-1515.
30.
Scatchard G: The attraction of proteins for small molecules and ions. Ann NY Acad Sci. 1949, 51: 660-672.CrossRef
31.
Terenius L: Selective retention of estrogen isomers in estrogen-dependent breast tumors of rats demonstrated by in vitro methods. Cancer Res. 1968, 28: 328-337.PubMed
32.
Toulas C, Guilbaud N, Delassus F, Bayard F, Faye JC: Modulation of the estrogen receptor structure, evidence of a heterogeneity. J Receptor Res. 1990, 10: 1-9.CrossRef
33.
Borràs M, Lacroix M, Legros N, Leclercq G: Estrogen receptor-negative/progesterone receptor-positive Evsa-T mammary tumor cells: a model for assessing the biological property of this peculiar phenotype of breast cancers. Cancer Lett. 1997, 120: 23-30.CrossRefPubMed
34.
Deugnier Y, Margules S, Brissot P, Deugnier MA, Bisconte JC, Bourel M, Ferrand B: Comparative study between biochemical and histological methods and image analysis in liver iron overload. J Clin Pathol . 1982, 35: 45-51.CrossRefPubMedPubMedCentral
35.
Weintraub J, Weintraub D, Redard M, Vassilakos P: Evaluation of estrogen receptors by immunocytochemistry on fine-needle aspiration biopsy specimens from breast tumors. Cancer. 1987, 60: 1163-1172.CrossRefPubMed
36.
Maaroufi Y, Ben Hardouze A, Leclercq G: Decrease of estrogen receptor binding capacity by calcium. J Receptor Signal Transduction Res. 1997, 17: 833-853.CrossRef
37.
Powel BL, de la Graza M, Clark GM, McGuire WL: Estrogen receptor measurement in low protein breast cancer cytosols. Breast Cancer Res Treat. 1981, 1: 33-35.CrossRef
38.
Trivedi S, Piccart M, Muquardt C, Gilot N, Hadiy S, Patel D, Leclercq G: Tamoxifen aziridine labeling of the estrogen receptor: potential utility in detecting biologically aggressive breast tumors. Breast Cancer Res Treat. 1996, 40: 231-241.CrossRefPubMed
39.
Maaroufi Y, Quivy J, Trivedi S, Gilot N, Leclercq G: 4-iodotamoxifen aziridine, a new affinity labeling agent for the rapid detection of estrogen receptor isoforms. J Steroid Biochem Mol Biol. 1998, 67: 95-104.CrossRefPubMed
40.
Harlow KW, Smith DN, Katzenellenbogen JA, Greene GL, Katzenellenbogen BS: Identification of cysteine 530 as the covalent attachment site of an affinity-labeling estrogen (ketonenestrol aziridine) and antiestrogen (tamoxifen aziridine) in the human estrogen receptor. J Biol Chem . 1989, 264: 17476-17485.PubMed
41.
Reese JC, Wooge CH, Katzenellenbogen BS: Identification of two cysteines closely positioned in the ligand binding pocket of the human estrogen receptor: roles in ligand binding and transcriptional activity. Mol Endocrinol. 1992, 6: 2160-2166.PubMed
42.
Fritsch M, Anderson I, Gorski J: Structural characterization of trypsinized estrogen receptor. Biochemistry. 1993, 32: 14000-14008.CrossRefPubMed
43.
Wilson EA, Yang F, Rees D: Estradiol and progesterone binding in uterine leiomyomata and in normal uterine tissues. Obstet Gynecol . 1980, 55: 20-24.PubMed
44.
Gregory MR, Notides AC: Characterization of two uterine proteases and their actions on the estrogen receptor. Biochemistry . 1982, 21: 6452-6458.CrossRefPubMed
45.
Navarro D, León L, Chirino R, Fernández L, Pestano J, Díaz-Chico BN: The two native estrogen receptor forms of 8S and 4S present in cytosol from human uterine tissues display opposite reactivities with the antiestrogen tamoxifen aziridine and the estrogen responsive element. J Steroid Biochem Mol Biol. 1998, 64: 49-58.CrossRefPubMed
46.
Schneider SL, Dao TL: Effect of Ca2+ and salt on forms of estradiol cytoplasmic receptor in human neoplasmic breast tissue. Cancer Res. 1977, 37: 382-387.PubMed
47.
Mauri FA, Veronese S, Frigo B, Girlando S, Losi L, Gambacorta M, Dalla Palma P, Barbareschi M: ER1D5 and H222 (ER-ICA) antibodies to human estrogen receptor protein in breast carcinomas: results of a multicentric comparative study. Appl Immunohistochem. 1994, 2: 157-163.
48.
Kraus WL, McInerney EM, Katzenellenbogen BS: Ligand-dependent, transcriptionally productive association of the amino- and carboxyl-terminal regions of a steroid hormone nuclear receptor. Proc Natl Acad Sci USA. 1995, 92: 12314-12318.CrossRefPubMedPubMedCentral
49.
McInerney EM, Tsai MJ, O'Malley BW, Katzenellenbogen BS: Analysis of estrogen receptor transcriptional enhancement by a nuclear hormone receptor coactivator. Proc Natl Acad Sci USA. 1996, 93: 10069-10073.CrossRefPubMedPubMedCentral
50.
Hochstrasser M: Ubiquitin, proteasomes, and the regulation of intracellular protein degradation. Curr Opin Cell Biol. 1995, 7: 215-223.CrossRefPubMed
51.
52.
Misiti S, Schomburg L, Yen PM, Chin WW: Expression and hormonal regulation of coactivator and corepressor genes. Endocrinology . 1998, 139: 2493-2500.CrossRefPubMed
53.
Folkers GE, van der Burg B, van der Saag PT: Promoter architecture, cofactors, and orphan receptors contribute to cell-specific activation of the retinoid acid receptor beta2 promoter. J Biol Chem. 1998, 273: 32200-32212.CrossRefPubMed
54.
Green S, Chambon P: Oestradiol induction of a glucocorticoid-responsive gene by a chimaeric receptor. Nature . 1987, 325: 75-78.CrossRefPubMed
Metadata
Title
Estrogen receptor of primary breast cancers: evidence for intracellular proteolysis
Authors
Younes Maaroufi
Marc Lacroix
Laurence Lespagnard
Fabrice Journé
Denis Larsimont
Guy Leclercq
Publication date
01-12-2000
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 6/2000
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr92

Other articles of this Issue 6/2000

Breast Cancer Research 6/2000 Go to the issue

Review

Molecular biology of breast cancer metastasis Clinical implications of experimental studies on metastatic inefficiency

Review

Molecular biology of breast cancer metastasis Molecular expression of vascular markers by aggressive breast cancer cells

Review

Molecular biology of breast cancer metastasis Genetic regulation of human breast carcinoma metastasis

Research article

P53 autoantibodies in 1006 patients followed up for breast cancer

Commentary

Breast cancer risk perception: what do we know and understand?

Review

Molecular biology of breast metastasis The use of mathematical models to determine relapse and to predict response to chemotherapy in breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits